{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:40:13Z","timestamp":1790073613376,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less than 45%. Guidelines recommend short\u2010acting nitrates, such as sublingual nitroglycerin, for the treatment of acute angina pectoris in patients with chronic coronary syndromes (CCSs), common comorbidities in HF. We evaluated safety, tolerability, and the pharmacodynamic interaction between vericiguat and nitroglycerin, coadministered in patients with CCSs. In this phase Ib, double\u2010blind, randomized, multicenter study, 36 patients with CCSs received either vericiguat 2.5\u00a0mg (up\u2010titrated every 2\u00a0weeks to 5\u00a0mg and 10\u00a0mg) or placebo. Patients also received nitroglycerin (0.4\u00a0mg sublingual). In total, 31 patients completed the study (vericiguat + nitroglycerin, <jats:italic>n<\/jats:italic>\u00a0=\u00a021; placebo + nitroglycerin, <jats:italic>n<\/jats:italic>\u00a0=\u00a010). There was no increase in treatment\u2010emergent adverse events (TEAEs) with vericiguat + nitroglycerin vs. placebo + nitroglycerin; three patients discontinued due to TEAEs (vericiguat + nitroglycerin, <jats:italic>n<\/jats:italic>\u00a0=\u00a01; placebo + nitroglycerin, <jats:italic>n<\/jats:italic>\u00a0=\u00a02). Decreases in mean blood pressure (BP; 6\u201310\u00a0mmHg systolic BP (SBP); 4\u20136\u00a0mmHg diastolic BP (DBP)) were independent of vericiguat exposure and occurred to a similar extent at trough and peak concentrations with all vericiguat doses and placebo. Coadministration of vericiguat with nitroglycerin in patients with CCSs was well tolerated, and the combination is unlikely to cause significant adverse effects beyond those known for nitroglycerin.<\/jats:p>","DOI":"10.1002\/cpt.2574","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T11:10:13Z","timestamp":1646737813000},"page":"1239-1247","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vericiguat in Combination with Short\u2010Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study"],"prefix":"10.1111","volume":"111","author":[{"given":"Michael","family":"Boettcher","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Bayer AG Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Dirk","family":"D\u00fcngen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiology Charit\u00e9 \u2013 Universitaetsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Donath","sequence":"additional","affiliation":[{"name":"SocraTec Research &amp; Development GmbH Erfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology University Hospital Heidelberg Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Werner","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Medicine II University Hospital Bonn Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra A.","family":"Thuermann","sequence":"additional","affiliation":[{"name":"Philipp Klee\u2010Institute of Clinical Pharmacology, Helios Klinikum Wuppertal Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Karakas","sequence":"additional","affiliation":[{"name":"Department of Cardiology University Heart &amp; Vascular Center Hamburg Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Besche","sequence":"additional","affiliation":[{"name":"Chrestos Concept GmbH &amp; Co. KG Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Koch","sequence":"additional","affiliation":[{"name":"Translational Studies Operations, Bayer AG Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gurniak","sequence":"additional","affiliation":[{"name":"Translational Studies Operations, Bayer AG Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Becker","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Bayer AG Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.028"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.049"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.09.008"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2007.08.010"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht296"},{"key":"e_1_2_12_9_1","volume-title":"NDA Approval Letter","author":"US Food and Drug Administration","year":"2021"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928"},{"key":"e_1_2_12_11_1","volume-title":"Verquvo [highlights of prescribing information]"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2018-0155"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_249"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.013"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00449"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.12.014"},{"key":"e_1_2_12_17_1","volume-title":"Vericiguat (VERQUVO) Integrated Review \u2010 Center for Drug Evaluation and Research","author":"US Food and Drug Administration","year":"2020"},{"key":"e_1_2_12_18_1","first-page":"293","article-title":"Safety, pharmacodynamic and pharmacokinetic characterization of vericiguat: key results from six phase I studies in healthy subjects","volume":"21","author":"Boettcher M.\u2010F.","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15734"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw593"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15922"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.1064"},{"key":"e_1_2_12_23_1","first-page":"1","volume-title":"Nitrolingual\u00ae pumpspray. Full prescribing information","author":"G. Pohl\u2010Boskamp GmbH & Co. KG","year":"2018"},{"key":"e_1_2_12_24_1","first-page":"749","article-title":"Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"39","author":"Khaybullina D.","year":"2014","journal-title":"P T"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:36:46Z","timestamp":1699364206000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/cpt.2574"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2574","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"2021-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}